Identification and Characterization of ATOH7-Regulated Target Genes and Pathways in Human Neuroretinal Development
Cells · 2024
DOI: 10.3390/cells13131142 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, 2024. Verfasst von David Atac und 7 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Medical Molecular Genetics, University of Zurich, 8952 Schlieren, Switzerland. Hauptthemen laut MEDLINE: Basic Helix-Loop-Helix Proteins, Retina, Induced Pluripotent Stem Cells. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 130 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Velux Stiftung, Velux Foundation.
Abstract (Originalsprache)
The proneural transcription factor atonal basic helix–loop–helix transcription factor 7 (ATOH7) is expressed in early progenitors in the developing neuroretina. In vertebrates, this is crucial for the development of retinal ganglion cells (RGCs), as mutant animals show an almost complete absence of RGCs, underdeveloped optic nerves, and aberrations in retinal vessel development. Human mutations are rare and result in autosomal recessive optic nerve hypoplasia (ONH) or severe vascular changes, diagnosed as autosomal recessive persistent hyperplasia of the primary vitreous (PHPVAR). To better understand the role of ATOH7 in neuroretinal development, we created ATOH7 knockout and eGFP-expressing ATOH7 reporter human induced pluripotent stem cells (hiPSCs), which were differentiated into early-stage retinal organoids. Target loci regulated by ATOH7 were identified by Cleavage Under Targets and Release Using Nuclease with sequencing (CUT&RUN-seq) and differential expression by RNA sequencing (RNA-seq) of wildtype and mutant organoid-derived reporter cells. Additionally, single-cell RNA sequencing (scRNA-seq) was performed on whole organoids to identify cell type-specific genes. Mutant organoids displayed substantial deficiency in axon sprouting, reduction in RGCs, and an increase in other cell types. We identified 469 differentially expressed target genes, with an overrepresentation of genes belonging to axon development/guidance and Notch signaling. Taken together, we consolidate the function of human ATOH7 in guiding progenitor competence by inducing RGC-specific genes while inhibiting other cell fates. Furthermore, we highlight candidate genes responsible for ATOH7-associated optic nerve and retinovascular anomalies, which sheds light to potential future therapy targets for related disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Medical Molecular Genetics, University of Zurich, 8952 Schlieren, Switzerland.
- UCL Great Ormond Street Institute of Child Health, University College London and NIHR Great Ormond Street Hospital Biomedical Research Centre, London WC1N 1EH, UK.
- Zurich Center for Integrative Human Physiology, University of Zurich, 8057 Zurich, Switzerland.
- Neuroscience Center Zurich, University and ETH Zurich, 8057 Zurich, Switzerland.
ORCID-Profile: David Atac, Kevin Maggi, Jordi Maggi, Elisa Cuevas, Jane C Sowden, Samuel Koller, Wolfgang Berger
Förderung
- Velux Stiftung
- Velux Foundation
Zitieren
APA
Atac, D., Maggi, K., Feil, S., Maggi, J., Cuevas, E., Sowden, J. C., Koller, S., & Berger, W. (2024). Identification and Characterization of ATOH7-Regulated Target Genes and Pathways in Human Neuroretinal Development. Cells. https://doi.org/10.3390/cells13131142
Vancouver
Atac D, Maggi K, Feil S, Maggi J, Cuevas E, Sowden JC, et al. Identification and Characterization of ATOH7-Regulated Target Genes and Pathways in Human Neuroretinal Development. Cells. 2024. doi:10.3390/cells13131142
BibTeX
@article{Atac2024,
author = {Atac, David and Maggi, Kevin and Feil, Silke and Maggi, Jordi and Cuevas, Elisa and Sowden, Jane C and Koller, Samuel and Berger, Wolfgang},
title = {Identification and Characterization of ATOH7-Regulated Target Genes and Pathways in Human Neuroretinal Development},
journal = {Cells},
year = {2024},
doi = {10.3390/cells13131142}
}
EUVIMED